Akebia Therapeutics, Inc.

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. 7.03%67.010.0%$1025.55m
NVAXNovavax, Inc. 8.25%102.14251.8%$827.54m
AMGNAmgen, Inc. 1.34%252.381.3%$703.09m
REGNRegeneron Pharmaceuticals, Inc. 1.07%627.522.5%$670.13m
GILDGilead Sciences, Inc. 1.01%77.091.0%$637.17m
BIIBBiogen, Inc. 0.61%280.581.6%$605.23m
VRTXVertex Pharmaceuticals, Inc. 0.58%296.161.9%$478.28m
VXRTVaxart, Inc. 24.19%9.910.0%$356.29m
ILMNIllumina, Inc. 1.65%376.353.5%$306.15m
ALXNAlexion Pharmaceuticals, Inc. -0.15%108.662.0%$216.87m
BMRNBioMarin Pharmaceutical, Inc. 1.33%127.744.3%$209.57m
SGENSeattle Genetics, Inc. 0.36%174.986.1%$193.08m
SRNESorrento Therapeutics, Inc. -0.63%8.011.8%$191.66m
IMMUImmunomedics, Inc. 1.50%41.9411.0%$179.66m
BNTXBioNTech SE 10.27%77.590.0%$172.63m

Company Profile

Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney disease. The firm also involves in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.